

Peter Van Etten

President & Chief Executive Officer
120 Wall Street, 19th Floor
New York, NY 10005
t: (212) 479-7515 f: (212) 479-7623
1-800-223-1138 pvanetten@jdrf.org
www.jdrf.org

July 26, 2005

Ms. Marlene H. Dortch Secretary, Federal Communications Commission 445 12th Street, S.W. Washington, D.C. 20554 Reference: ET Docket No. 05-213

Re: Continuous Glucose Monitor Support for FCC Authorization

Dear Ms. Dortch:

I am writing to underscore the potential positive impact that continuous glucose sensing technologies may have in the field of diabetes and to request that technologies presented to the FCC be reviewed quickly and without undue delay. Continuous glucose sensing technologies hold considerable promise to both improve the quality of life for people with diabetes and to significantly reduce both the short term and long term compactions of complications such as hypoglycemia (low blood sugar), retinopathy (eye disease that can lead to blindness) and nephropathy (kidney disease that can be life threatening). A number of studies, such as the Diabetes Control and Complications Trial (DCCT), have consistently shown that tighter glucose control can reduce the costly and debilitating complications associated with diabetes. Ultimately, a continuous glucose sensor will be an integral component of an artificial pancreas, which holds the promise of restoring near-euglycemia (normal, healthy blood sugar levels) to people with diabetes.

The Juvenile Diabetes Research Foundation International (JDRF) was founded by parents of children with juvenile diabetes and has one mission: to find a cure for diabetes and its complications through the support of research. JDRF has spent more than \$800 million since our founding in 1970 on diabetes research, including over \$85 million in 2004 alone. More than 80 percent of JDRF's expenditures directly support research and research-related education. Of the three main cure goals that are part of the JDRF cure mission: 1. Restoring normal blood sugar levels, 2. Preventing and reversing complications, and 3. Preventing type 1 diabetes, continuous glucose sensors and ultimately an artificial pancreas may facilitate the restoration of normal glucose levels (Goal 1.), which would in turn prevent a significant amount of diabetic domplications (Goal 2).

Please feel free to contact me if I can provide any additional information with regard to this matter.

Sincerely yours,

Peter Van Etten President & CEO